ARGX (argenx SE) Inventories, Raw Materials & Components: $0 Mil (As of Mar. 2026)


ARGX argenx SE ARGX
80 GF Score
Price $912.46
GF Value $1,363.68
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Inventories, Raw Materials & Components?

argenx SE ARGX +3.01% 80 Inventories, Raw Materials & Components is $0 Mil as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,363.68 (Significantly Undervalued). The stock has 5 warning signs investors should review.

argenx SE's inventories, raw materials & components for the quarter that ended in Mar. 2026 was $0 Mil.

argenx SE's quarterly raw materials increased from Sep. 2025 ($0 Mil) to Dec. 2025 ($336 Mil) but then declined from Dec. 2025 ($336 Mil) to Mar. 2026 ($0 Mil).

argenx SE's annual raw materials increased from Dec. 2023 ($241 Mil) to Dec. 2024 ($338 Mil) but then declined from Dec. 2024 ($338 Mil) to Dec. 2025 ($336 Mil).

argenx SE Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for argenx SE's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Inventories, Raw Materials & Components Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.13 126.05 240.84 337.83 335.54

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 258.08 0.00 335.54 0.00
ARGX
80GF Score
argenx SE ARGX
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0 Mil mean?
argenx SE (ARGX) has a Inventories, Raw Materials & Components of $0 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on argenx SE and its competitors.
Is argenx SE's Inventories, Raw Materials & Components too high?
argenx SE's current Inventories, Raw Materials & Components is $0 Mil. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Inventories, Raw Materials & Components compare to VRTX and REGN?
argenx SE's Inventories, Raw Materials & Components of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on argenx SE and its competitors. argenx SE's current Inventories, Raw Materials & Components is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,363.68, compared to a current price of $912.46 — trading 33.1% below its estimated fair value. The current Inventories, Raw Materials & Components is $0 Mil. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For argenx SE (ARGX), the current Inventories, Raw Materials & Components is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $912.46 is trading 33.1% below its estimated GF Value™ of $1,363.68. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

  • Inventories, Raw Materials & Components: $0 Mil
  • GF Value™: $1,363.68 vs. price of $912.46 (33.1% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score

Get the complete analysis for ARGX

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$912.46
Price
$1,363.68
GF Value